Claims
- 1. A method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, said method comprising administering to the woman an effective amount of the compound of formula (I)
- 2. The method according to claim 1 wherein compound (I) is ospemifene.
- 3. The method according to claim 1 or 2 wherein the atrophy is urogenital atrophy.
- 4. A method for treatment or prevention of symptoms related to skin atrophy, or to epithelial or mucosal atrophy in women, said method comprising administering to the woman an effective amount of the compound of formula (I)
- 5. The method according to claim 4 wherein compound (I) is ospemifene.
- 6. The method according to claim 1 wherein the atrophy is urogenital atrophy.
- 7. The method according to claim 6 wherein the symptoms are urinary symptoms.
- 8. The method according to claim 8 wherein the urinary symptoms are micturation disorders, dysuria, hematuria, urinary frequency, sensation of urgency, urinary tract infections, urinary tract inflammation, nocturia, urinary incontinence, urge incontinence or involuntary urinary leakage.
- 9. The method according to claim 6 wherein the symptoms are vaginal symptoms.
- 10. The method according to claim 9 wherein the vaginal symptoms are irritation, itching, burning, maladorous discharge, infection, dyspareunia, leukorrhea, vulvar pruritus, feeling of pressure, postcoital bleeding, vaginal dryness and difficulty in sexual arousal.
- 11. The method according to claims 1 or 4 wherein compound (I), its isomer, salt or ester is administered orally, topically, transdermally, intravaginally or subcutaneously.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of International Application No. PCT/FI01/00414 filed May 2, 2001 designating the U.S., which was published under PCT Article 21(2) in English as International Publication No. WO 02/07718, and which claims priority to U.S. patent application Ser. No. 09/625,199, filed Jul. 21, 2000, now U.S. Pat. No. 6,245,819, each application being incorporated by reference herein in its entirety.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/FI01/00414 |
May 2001 |
US |
Child |
10162708 |
Jun 2002 |
US |